ストックスクリーナーアプリを入手
19.17
2.62%
0.49
アフターアワーズ：
19.17
前日終値:
$18.68
開ける：
$18.78
24時間の取引高:
180.66K
Relative Volume:
0.90
時価総額：
$2.47B
収益：
$17.20M
当期純損益:
$-102.16M
株価収益率:
-22.66
EPS:
-0.8458
ネットキャッシュフロー:
$-57.32M
1週間 パフォーマンス:
+13.90%
1か月 パフォーマンス:
-1.69%
6か月 パフォーマンス:
+17.18%
1年 パフォーマンス:
+7.21%
1日の値動き範囲:
$18.63
$19.34
1週間の範囲:
$16.79
$19.34
52週間の値動き範囲:
$9.61
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
19.17 | 2.41B | 17.20M | -102.16M | -57.32M | -0.8458 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | アップグレード | Jefferies | Hold → Buy |
| 2025-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-12-23 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-24 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-29 | アップグレード | Jefferies | Hold → Buy |
| 2024-07-23 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-07 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 開始されました | William Blair | Outperform |
| 2022-12-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-09-06 | 開始されました | Piper Sandler | Overweight |
| 2021-04-07 | アップグレード | Maxim Group | Hold → Buy |
| 2020-12-22 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-12-04 | ダウングレード | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2020-05-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-31 | 再開されました | H.C. Wainwright | Buy |
| 2018-03-22 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-08-31 | 開始されました | Oppenheimer | Outperform |
| 2017-06-08 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Mesoblast Ltd Adr (MESO) 最新ニュース
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment - GlobeNewswire Inc.
Mesoblast stock reaches 52-week high at 21.05 USD - Investing.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com India
Mesoblast announces board leadership changes as company evolves By Investing.com - Investing.com India
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - inkl
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales By Investing.com - Investing.com India
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLC - Defense World
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - ADVFN Brasil
Press Release: Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - 富途牛牛
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Krispy Kreme Inc (DNUT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
MESOMesoblast Ltd ADR Short Interest - Finviz
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd Share Price ADR Each Representing 10 Ord Shares SPON - Hargreaves Lansdown
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart.com
MESO Financial Statements & ChartsMesoblast LtdAdr MacroTrends - CMLviz
MESO Pivot Points, Technical Analysis and Moving AveragesMesoblast LtdAdr Technicals - CMLviz
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod - Yahoo Finance
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Novartis
How many stocks fighting COVID-19 have maintained their momentum? - Stockhead
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
MESO Stock Price and Chart — NASDAQ:MESO - TradingView
MSB Stock Price and Chart — ASX:MSB - TradingView — Track All Markets
Mesoblast Limited (MESO) stock price, news, quote and history - Yahoo Finance UK
MESO Stock Price | Mesoblast Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Mesoblast Ltd Adr (MESO) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):